In April 2017, Celgene Corporation (Nasdaq: CELG) entered into a long-term partnership with Antengene by licensing rights to develop, manufacture and commercialize its TORC1/2 kinase inhibitor, CC-223 (ATG-008 for Antengene), in East and Southeast Asia.

This marks the first licensing deal for Celgene in the Asia-Pacific region, creates the foundation for a strategic partnership between the two companies and embodies the beginning of a long-term collaboration.

In May 2018, Antengene started a broad strategic partnership with Karyopharm Therapeutics Inc. (Nasdaq: KPTI) to develop, manufacture and commercialize four of Karyopharm’s novel, first-in-class, clinical-stage oral drug candidates in multiple countries/regions in Asia.

This strategic partnership brings promising product candidates to our pipeline. We will continue to broaden our development in multiple disease areas, with a focus in oncology and influenza.

In November 2019, Antengene Corporation entered into a licensing agreement with AstraZeneca (LSE/STO/NYSE: AZN), under which Antengene obtained the exclusive rights to develop, manufacture and commercialize the small molecule selective ERK1/2 inhibitor AZD0364 worldwide.